JP7097880B2 - Ｍａｌｔ１分解のための化合物 - Google Patents

Ｍａｌｔ１分解のための化合物 Download PDF

Info

Publication number
JP7097880B2
JP7097880B2 JP2019523739A JP2019523739A JP7097880B2 JP 7097880 B2 JP7097880 B2 JP 7097880B2 JP 2019523739 A JP2019523739 A JP 2019523739A JP 2019523739 A JP2019523739 A JP 2019523739A JP 7097880 B2 JP7097880 B2 JP 7097880B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537599A (ja
JP2019537599A5 (OSRAM
Inventor
メルニック，アリ，エム．
ギャバス，ロレーナ，フォンタン
アス，イルカイ
キャサレーナ，ガブリエラ
グレイ，ナタナエル，エス．
スコット，デイビッド，エー．
ハッチャー，ジョン
デュ，グァンユェン
ウー，ハオ
ヂァオ，ヂー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Cornell University
Original Assignee
Boston Childrens Hospital
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Cornell University filed Critical Boston Childrens Hospital
Publication of JP2019537599A publication Critical patent/JP2019537599A/ja
Publication of JP2019537599A5 publication Critical patent/JP2019537599A5/ja
Application granted granted Critical
Publication of JP7097880B2 publication Critical patent/JP7097880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019523739A 2016-11-01 2017-10-31 Ｍａｌｔ１分解のための化合物 Active JP7097880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416066P 2016-11-01 2016-11-01
US62/416,066 2016-11-01
PCT/US2017/059234 WO2018085247A1 (en) 2016-11-01 2017-10-31 Compounds for malt1 degradation

Publications (3)

Publication Number Publication Date
JP2019537599A JP2019537599A (ja) 2019-12-26
JP2019537599A5 JP2019537599A5 (OSRAM) 2020-12-10
JP7097880B2 true JP7097880B2 (ja) 2022-07-08

Family

ID=62077048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523739A Active JP7097880B2 (ja) 2016-11-01 2017-10-31 Ｍａｌｔ１分解のための化合物

Country Status (4)

Country Link
US (1) US10689366B2 (OSRAM)
EP (1) EP3535254A4 (OSRAM)
JP (1) JP7097880B2 (OSRAM)
WO (1) WO2018085247A1 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3341007B1 (en) 2015-08-28 2020-12-23 Cornell University Malt1 inhibitors and uses thereof
HK1252752A1 (zh) * 2015-11-13 2019-05-31 Novartis Ag 新型吡唑并嘧啶衍生物
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
JP7142022B2 (ja) * 2017-03-08 2022-09-26 コーネル・ユニバーシティー Ｍａｌｔ１の阻害剤およびそれらの使用
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
US11571427B2 (en) 2017-12-28 2023-02-07 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
IL298250B2 (en) 2018-04-12 2025-01-01 Bayer Ag N-(cyclopropylmethyl)-5-(methylsulfonyl)-N-{1-[1-(pyrimidin-2-yl)-H1-1, 2, 4-triazol-5-yl]ethyl}benzamide derivatives and pyridine-carboxamide derivatives are compatible as pesticides
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
LT3784663T (lt) 2018-04-23 2023-10-25 Celgene Corporation Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui
AU2019260016B2 (en) 2018-04-25 2022-11-17 Bayer Aktiengesellschaft Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019242625A1 (zh) * 2018-06-20 2019-12-26 上海科技大学 制备来那度胺衍生物的方法
AU2019390863B2 (en) * 2018-11-28 2025-02-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
EP4671268A2 (en) 2019-03-21 2025-12-31 Lonza Sales AG METHOD FOR PREPARING EXTRACELLULAR VESICLES
AU2020241903A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
EP3986397A4 (en) * 2019-06-24 2023-05-10 Dana-Farber Cancer Institute, Inc. Hck degraders and uses thereof
BR112022000942A2 (pt) 2019-07-23 2022-05-17 Bayer Ag Compostos de heteroaril-triazol como pesticidas
UY38911A (es) 2019-10-09 2021-05-31 Bayer Ag Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos
JP2023508914A (ja) * 2019-12-20 2023-03-06 カリコ ライフ サイエンシーズ エルエルシー プロテインチロシンホスファターゼ分解剤及びその使用方法
CA3161339A1 (en) * 2019-12-27 2021-07-01 Schrodinger, Inc. Cyclic compounds and methods of using same
AU2021259858B2 (en) * 2020-04-23 2024-12-19 University Of Iowa Research Foundation GPER proteolytic targeting chimeras
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230192685A1 (en) 2020-05-27 2023-06-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
WO2021257650A1 (en) * 2020-06-17 2021-12-23 Dana-Farber Cancer Institute, Inc. Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
WO2021262969A1 (en) 2020-06-24 2021-12-30 The General Hospital Corporation Materials and methods of treating cancer
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
CN116710089A (zh) * 2020-11-12 2023-09-05 莫诺泰罗斯疗法公司 治疗癌症的材料和方法
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
WO2022164830A1 (en) * 2021-01-29 2022-08-04 Eurofins Discoverx Corporation Molecular glue screening assays and methods for practicing same
KR20240130085A (ko) 2021-12-30 2024-08-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용
JP2025503727A (ja) * 2022-01-18 2025-02-04 オーリジーン オンコロジー リミテッド Ｍａｌｔ－１阻害剤としての置換二環式複素環関連出願の相互参照 この出願は、２０２２年１月１８日に提出されたインド仮特許出願第２０２２４１００２８５９号に対する優先権を主張する。この仮出願の全内容は、参照により本明細書に組み込まれる。
WO2023143249A1 (zh) * 2022-01-28 2023-08-03 上海齐鲁制药研究中心有限公司 靶向malt1的蛋白降解化合物
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
CN119486728A (zh) * 2022-02-25 2025-02-18 特吉德治疗公司 粘膜相关淋巴组织淋巴瘤易位蛋白1的蛋白水解靶向嵌合
EP4536656A1 (en) 2022-06-06 2025-04-16 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043347A1 (en) 2003-07-24 2005-02-24 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
WO2012071414A2 (en) 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
WO2015105518A1 (en) 2014-01-13 2015-07-16 Facebook, Inc. Systems and methods for priority-based digital content downloading
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2015187827A1 (en) 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375984T1 (de) * 1999-07-07 2007-11-15 Astrazeneca Uk Ltd Chinazolin derivate
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2018118598A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043347A1 (en) 2003-07-24 2005-02-24 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
WO2012071414A2 (en) 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
WO2015105518A1 (en) 2014-01-13 2015-07-16 Facebook, Inc. Systems and methods for priority-based digital content downloading
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2015187827A1 (en) 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
奥村文彦，Elongin BC型 E3ユビキチンリガーゼと細胞機能制御，生化学，2013年，85(2)，76-88

Also Published As

Publication number Publication date
JP2019537599A (ja) 2019-12-26
WO2018085247A1 (en) 2018-05-11
US10689366B2 (en) 2020-06-23
EP3535254A1 (en) 2019-09-11
EP3535254A4 (en) 2020-06-24
US20190263785A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP7097880B2 (ja) Ｍａｌｔ１分解のための化合物
JP7260521B2 (ja) タウタンパク質分解の化合物
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7142022B2 (ja) Ｍａｌｔ１の阻害剤およびそれらの使用
JP6491202B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP2021514958A (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
JP7427812B2 (ja) 血漿カリクレインの阻害剤およびその使用
JP6989505B2 (ja) Ｍａｌｔ１阻害剤およびその使用
KR20150126670A (ko) Ras 억제제 및 그의 용도
CA2968884A1 (en) Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
JP2024529487A (ja) Ｒｏｃｋ２阻害剤およびその使用
JP7185631B2 (ja) 抗線維化化合物
JP2021529174A (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
US20230322747A1 (en) Oxadiazole hdac6 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220628

R150 Certificate of patent or registration of utility model

Ref document number: 7097880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250